Creative Biolabs offers comprehensive, integrated services to support the preclinical testing of novel anticancer immunotherapies, including in vivo efficacy evaluation, accelerating IO development.
Learn More →Human Kidney Cell ACHN based Proliferation Assay Service
Creative Biolabs' ACHN based proliferation assay service is engineered to provide actionable, quantitative data that directly informs your lead optimization and investigational new drug (IND) efforts. We deliver the complete spectrum of efficacy data: precise inhibitory concentration 50% (IC50), growth inhibition concentration 50% (GI50), and lethal concentration 50% (LC50) values, which are essential for defining a compound's potency, therapeutic window, and mechanism of action (MOA).
What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The ACHN cell line, a cornerstone model for human kidney adenocarcinoma (RCC), is indispensable for mimicking aggressive RCC behavior in vivo. Accurate measurement of proliferation inhibition in this line is the most critical initial readout for assessing new therapeutic molecules, including small molecules and IO biologics. Our service leverages this high-relevance model to address fundamental questions in therapeutic development: elucidating the MOA, generating precise dose-response profiles for structure-activity relationship (SAR) analysis, and evaluating crucial drug-drug synergy for modern combinatorial strategies.
Defining Therapeutic Potential with the ACHN Assay
Our approach utilizes a modular suite of assessment technologies, ensuring the method aligns perfectly with your compound's characteristics:
Feature Assay
We use the luminescence based viability assay (ATP quantification) for superior sensitivity and reliable IC50 determination in high-throughput primary screening.
Mechanistic Assays
We offer BrdU incorporation (for S-phase activity) and LDH release (for cytotoxicity) to dissect complex, dual-function agents. This provides direct evidence of cell cycle disruption and validates novel targets.
Partner with Creative Biolabs to precisely define the anti-proliferative efficacy of your lead compounds and accelerate your journey toward clinical translation.
Workflow Precision: From Compound QC to Final Data Package
Creative Biolabs executes every ACHN proliferation assay through a strictly controlled, stage-gated workflow designed for maximum reproducibility and minimal variability.
Publication
This study investigated whether functional interleukin-2 receptors (IL-2R) are expressed on RCC cells, challenging the view that IL-2 only acts through the immune system. Using four RCC cell lines (A-498, ACHN, Caki-1, Caki-2), the authors confirmed gene and protein expression of IL-2R subunits. Crucially, recombinant human IL-2 (rhIL-2) exerted dual, cell line- and concentration-dependent effects: it could either inhibit proliferation/induce apoptosis or promote survival/proliferation. These findings reveal a direct IL-2 pathway on RCC cells, suggesting its therapeutic action extends beyond immune activation and supporting personalized treatment.
Fig.1 BrdU incorporation assay reveals the proliferative effect of rhIL-2 on RCC cell lines. 1
Why Choose Us
Creative Biolabs is the partner of choice for RCC drug development, committed to superior data quality. Our superior luminescence technology uses ATP quantification for unmatched sensitivity and clarity over colorimetric assays, virtually eliminating artifacts. We offer validated mechanistic dissection of complex agents, exemplified by successfully dissecting the ACHN cell's IL-2 response, which shows concentration-dependent dual effects (proliferation vs. apoptosis). Our predictive translational validation is proven, as ACHN in vitro results (e.g., for apigenin) consistently correlate with in vivo tumor suppression, giving high confidence for lead progression.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q: Can this assay be used to test large biologics, or is it limited to small molecule inhibitors?
A: Absolutely. The ACHN model is validated for both. Our recent studies on the IL-2 receptor signaling pathway highlight our capability to dissect the complex, concentration-dependent effects of large therapeutic molecules. We tailor the dosing and incubation to suit your compound type.
Q: I suspect my compound is causing cell death, not just growth arrest. Which assay should I choose?
A: We recommend combining our featured luminescence assay (for overall viability) with a specific cytotoxicity assay, such as the LDH release or propidium iodide (PI) staining assay. This combination allows us to precisely calculate both the GI50 and the LC50, giving you a complete profile.
Q: How do you ensure the ACHN cells maintain their physiological relevance during the assay?
A: We use rigorous quality control, including regular cell authentication and testing for mycoplasma. Furthermore, our validated protocols use optimized culture conditions and low-passage cells to maintain the ACHN line's pathological characteristics, ensuring highly translational results.
Customer Review
-
High-Quality Data
Using Creative Biolabs' service in our research has significantly improved our confidence in our GI50 data. The low background of the luminescence assay was a distinct advantage over the MTT method we previously used, especially with our slightly fluorescent compounds. – Jn*S*mh. -
Speed & Customization
Using Creative Biolabs' service in our research has significantly improved the speed of our compound efficacy testing. Their team customized the protocol to handle our unique vehicle solvent, avoiding artifacts and accelerating our lead optimization efforts by several weeks. – R*tP*rz
Related Services
To complement the ACHN based proliferation assay, we recommend the following services offered by Creative Biolabs to further validate your drug candidate and accelerate your program:
In Vivo Efficacy
Immunogenicity Prediction
Creative Biolabs' sensitive immunogenicity assessment technology (SIAT) offers in silico and in vitro screening following guidelines to address the critical safety issue of immunogenicity in biologics.
Learn More →Contact Us
Creative Biolabs provides the definitive human kidney cell ACHN based proliferation assay service, delivering precise pharmacological metrics and complex mechanistic insights essential for advancing your RCC pipeline. Our expertise, combined with superior luminescence technology, provides the high-confidence data required for critical decision-making.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Grigolo, Sophie, Isabelle Fellay, and Luis Filgueira. "IL-2 Receptor Expression in Renal Cell Carcinoma Cells: IL-2 Influences Cell Survival and Induces Cell Death." Current Issues in Molecular Biology 47.10 (2025): 830. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cimb47100830
Download our brochureLoading case studies...
Online Inquiry